Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives $59.82 Consensus Target Price from Analysts
Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Free Report) has been assigned an average rating of “Buy” from the nineteen analysts that are covering the company, MarketBeat reports. One analyst has rated the stock with a hold recommendation, seventeen have assigned a buy recommendation and one has given a strong buy recommendation to the company. The […]
Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Free Report) has been assigned an average rating of “Buy” from the nineteen analysts that are covering the company, MarketBeat reports. One analyst has rated the stock with a hold recommendation, seventeen have assigned a buy recommendation and one has given a strong buy recommendation to the company. The […]
